Zetmax Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 50.00 K
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
About Zetmax Pharma
Zetmax Pharma Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 May 2019 (Five years and eight months 27 days old ). Its registered office is in Coimbatore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 50.00 K , as per Ministry of Corporate Affairs (MCA) records.
Balakrishnandar Kirouchenane, Palaniappan Krishnan, Duraisamy Gayathri, and One other member serve as directors at the Company.
Company Details
-
Location
Coimbatore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909TN2019PTC129381
-
Company No.
129381
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 May 2019
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Zetmax Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palaniappan Krishnan
|
Director | 21-May-2019 | Current |
|
Balakrishnandar Kirouchenane
|
Director | 21-May-2019 | Current |
|
Duraisamy Gayathri
|
Director | 21-May-2019 | Current |
|
Subashini
|
Director | 26-Feb-2021 | Current |
Financial Performance of Zetmax Pharma.
Zetmax Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zetmax Pharma?
In 2020, Zetmax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Madhamalai Tea Plantation Private LimitedBalakrishnandar Kirouchenane is a mutual person
-
Pentaspark Healthcare Private Limited
Balakrishnandar Kirouchenane is a mutual person
-
-
Signbro Pharma Private Limited
Duraisamy Gayathri is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zetmax Pharma?
Unlock and access historical data on people associated with Zetmax Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zetmax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zetmax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
